These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 31595822

  • 1. A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.
    Chintakuntlawar AV, Yin J, Foote RL, Kasperbauer JL, Rivera M, Asmus E, Garces NI, Janus JR, Liu M, Ma DJ, Moore EJ, Morris JC, Neben-Wittich M, Price DL, Price KA, Ryder M, Van Abel KM, Hilger C, Samb E, Bible KC.
    Thyroid; 2019 Nov; 29(11):1615-1622. PubMed ID: 31595822
    [Abstract] [Full Text] [Related]

  • 2. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, Rassner M, Boerries M, Zielke A, la Rosee P, Meyer PT, Kroiss M, Weißenberger C, Schumacher T, Metzger P, Weiss H, Smaxwil C, Laubner K, Duyster J, von Bubnoff N, Miething C, Thomusch O.
    Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
    [Abstract] [Full Text] [Related]

  • 3. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
    Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME.
    J Immunother Cancer; 2018 Jul 11; 6(1):68. PubMed ID: 29996921
    [Abstract] [Full Text] [Related]

  • 4. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
    Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME.
    Thyroid; 2019 Aug 11; 29(8):1036-1043. PubMed ID: 31319771
    [Abstract] [Full Text] [Related]

  • 5. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.
    Fan D, Ma J, Bell AC, Groen AH, Olsen KS, Lok BH, Leeman JE, Anderson E, Riaz N, McBride S, Ganly I, Shaha AR, Sherman EJ, Tsai CJ, Kang JJ, Lee NY.
    Cancer; 2020 Jan 15; 126(2):444-452. PubMed ID: 31593317
    [Abstract] [Full Text] [Related]

  • 6. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM, Ryder MM, Hilger CR, Bible KC.
    Thyroid; 2017 Jul 15; 27(7):923-927. PubMed ID: 28471306
    [Abstract] [Full Text] [Related]

  • 7. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.
    Rao SN, Zafereo M, Dadu R, Busaidy NL, Hess K, Cote GJ, Williams MD, William WN, Sandulache V, Gross N, Gunn GB, Lu C, Ferrarotto R, Lai SY, Cabanillas ME.
    Thyroid; 2017 May 15; 27(5):672-681. PubMed ID: 28068873
    [Abstract] [Full Text] [Related]

  • 8. Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report.
    Barbaro D, Forleo R, Profilo MA, Lapi P, Giani C, Torregrossa L, Macerola E, Materazzi G.
    Front Endocrinol (Lausanne); 2024 May 15; 15():1389294. PubMed ID: 39045273
    [Abstract] [Full Text] [Related]

  • 9. Immunotherapy in anaplastic thyroid cancer: Case series.
    Shih SR, Chen KH, Lin KY, Yang PC, Chen KY, Wang CW, Chen CN, Lin CF, Lin CC.
    J Formos Med Assoc; 2022 Jun 15; 121(6):1167-1173. PubMed ID: 35031200
    [Abstract] [Full Text] [Related]

  • 10. A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer.
    Lee NY, Riaz N, Wu V, Brinkman T, Tsai CJ, Zhi W, Fetten J, Ho A, Wong RJ, Ghossein R, Tuttle M, Fagin J, Pfister DG, Sherman E.
    Thyroid; 2022 Jul 15; 32(7):799-806. PubMed ID: 35521657
    [Abstract] [Full Text] [Related]

  • 11. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy.
    Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC.
    Thyroid; 2011 Jan 15; 21(1):25-30. PubMed ID: 21162687
    [Abstract] [Full Text] [Related]

  • 12. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
    Soll D, Bischoff P, Frisch A, Jensen M, Karadeniz Z, Mogl MT, Horst D, Penzkofer T, Spranger J, Keilholz U, Mai K.
    BMC Endocr Disord; 2024 Feb 22; 24(1):25. PubMed ID: 38383419
    [Abstract] [Full Text] [Related]

  • 13. High efficacy of chemoradiation therapy sensitized by weekly docetaxel for anaplastic thyroid cancer.
    Onoda N, Kashiwagi S, Noda S, Kawajiri H, Takashima T, Ishikawa T, Hirakawa K.
    Anticancer Res; 2013 Aug 22; 33(8):3445-8. PubMed ID: 23898117
    [Abstract] [Full Text] [Related]

  • 14. Pembrolizumab for anaplastic thyroid cancer: a case study.
    Aghajani MJ, Cooper A, McGuire H, Jeffries T, Saab J, Ismail K, de Souza P, Bray V, Fazekas de St Groth B, Niles N, Roberts TL.
    Cancer Immunol Immunother; 2019 Dec 22; 68(12):1921-1934. PubMed ID: 31637475
    [Abstract] [Full Text] [Related]

  • 15. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma.
    Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, Iyer P, Hofmann MC, Zafereo M.
    Thyroid; 2018 Jul 22; 28(7):945-951. PubMed ID: 29742974
    [Abstract] [Full Text] [Related]

  • 16. Boosted abscopal effect from radiotherapy and pembrolizumab in anaplastic thyroid cancer: a mini-review and case report.
    Goh D, Lim KH, Sudirman SRB, Ang MK, Chua MLK, Lim CM.
    Chin Clin Oncol; 2023 Oct 22; 12(5):57. PubMed ID: 37964542
    [Abstract] [Full Text] [Related]

  • 17. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
    Adam P, Kircher S, Sbiera I, Koehler VF, Berg E, Knösel T, Sandner B, Fenske WK, Bläker H, Smaxwil C, Zielke A, Sipos B, Allelein S, Schott M, Dierks C, Spitzweg C, Fassnacht M, Kroiss M.
    Front Endocrinol (Lausanne); 2021 Oct 22; 12():712107. PubMed ID: 34475850
    [Abstract] [Full Text] [Related]

  • 18. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y, Onoda N, Ito KI, Sugitani I, Takahashi S, Yamaguchi I, Kabu K, Tsukada K.
    Thyroid; 2017 Sep 22; 27(9):1142-1148. PubMed ID: 28635560
    [Abstract] [Full Text] [Related]

  • 19. Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report.
    Luongo C, Porcelli T, Sessa F, De Stefano MA, Scavuzzo F, Damiano V, Klain M, Bellevicine C, Matano E, Troncone G, Schlumberger M, Salvatore D.
    Curr Oncol; 2021 Dec 16; 28(6):5401-5407. PubMed ID: 34940089
    [Abstract] [Full Text] [Related]

  • 20. Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience.
    Park J, Jung HA, Shim JH, Park WY, Kim TH, Lee SH, Kim SW, Ahn MJ, Park K, Chung JH.
    Eur J Endocrinol; 2021 May 06; 184(6):837-845. PubMed ID: 33852431
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.